Evidence map›Paper›PMID 35562945›Full record

ReviewInternational journal of molecular sciences2022

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF.

Maria Barilli, Maria Cristina Tavera, Serafina Valente, Alberto Palazzuoli

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06002321 (Right Ventricular Dysfunction in Chronic Heart Failure), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06002321 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

Right Ventricular Dysfunction in Chronic Heart Failure: Clinical Laboratory and Echocardiographic Characteristics

Typeobservational_patient_registrySponsorUniversity of SienaRan2023 to 2026Enrolled1,000ConditionsChronic Heart Failure, Right Ventricular Dysfunction, Right Heart FailureArmsEchocardiography, Laboratory Test
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maria BarilliDepartment of Medical Biotechnologies, Division of Cardiology, Le Scotte Hospital, 53100 Siena, Italy.
Maria Cristina TaveraCardio-Thoracic and Vascular Department, Division of Cardiology, Le Scotte Hospital, 53100 Siena, Italy.
Serafina ValenteCardio-Thoracic and Vascular Department, Division of Cardiology, Le Scotte Hospital, 53100 Siena, Italy.
Alberto PalazzuoliCardiovascular Diseases Unit, Cardio-Thoracic and Vascular Department, Le Scotte Hospital, 53100 Siena, Italy.ORCID 0000-0002-6235-984X
Ospedale Santa Maria alle Scotte · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most important diagnostic challenges in clinical practice is the distinction between pulmonary hypertension (PH) due to primitive pulmonary arterial hypertension (PAH) and PH due to left heart diseases. Both conditions share some common characteristics and pathophysiological pathways, making the two processes similar in several aspects. Their diagnostic differentiation is based on hemodynamic data on right heart catheterization, cardiac structural modifications, and therapeutic response. More specifically, PH secondary to heart failure with preserved ejection fraction (HFpEF) shares features with type 1 PH (PAH), especially when the combined pre- and post-capillary form (CpcPH) takes place in advanced stages of the disease. Right ventricular (RV) dysfunction is a common consequence related to worse prognosis and lower survival. This condition has recently been identified with a new classification based on clinical signs and progression markers. The role and prevalence of PH and RV dysfunction in HFpEF remain poorly identified, with wide variability in the literature reported from the largest clinical trials. Different parenchymal and vascular alterations affect the two diseases. Capillaries and arteriole vasoconstriction, vascular obliteration, and pulmonary blood fluid redistribution from the basal to the apical district are typical manifestations of type 1 PH. Conversely, PH related to HFpEF is primarily due to an increase of venules/capillaries parietal fibrosis, extracellular matrix deposition, and myocyte hypertrophy with a secondary "arteriolarization" of the vessels. Since the development of structural changes and the therapeutic target substantially differ, a better understanding of pathobiological processes underneath PH-HFpEF, and the identification of potential maladaptive RV mechanisms with an appropriate diagnostic tool, become mandatory in order to distinguish and manage these two similar forms of pulmonary hypertension.

Indexed as

Heart FailureHypertension, PulmonaryPulmonary Arterial HypertensionVentricular Dysfunction, RightHeart VentriclesHumansStroke VolumeVentricular Function, RightHFpEFimagingpulmonary hypertensionright ventricle

Identifiers

PMID35562945
PMCPMC9103781
OpenAlexW4224266770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.